UY34550A - Bencilpirazoles sustituidos - Google Patents

Bencilpirazoles sustituidos

Info

Publication number
UY34550A
UY34550A UY0001034550A UY34550A UY34550A UY 34550 A UY34550 A UY 34550A UY 0001034550 A UY0001034550 A UY 0001034550A UY 34550 A UY34550 A UY 34550A UY 34550 A UY34550 A UY 34550A
Authority
UY
Uruguay
Prior art keywords
bencilpirazoles
substituted
pag273
escanear
sgdd
Prior art date
Application number
UY0001034550A
Other languages
English (en)
Spanish (es)
Inventor
Dr Hans Briem
Dr Gerhard Siemeister
Dr Mark Jean Gnoth
Dr Marion Hitchcock
Dr Anne Mengel
Dr Knut Eis
Dr Amaury Ernesto Fernandez-Montalvan
Dr Stefan Prechtl
Dr Anja Richter
Dr Vera Puetter
Stegmann Christian
Dr Simon Holton
Dr Cornelia Preusse
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of UY34550A publication Critical patent/UY34550A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Particle Accelerators (AREA)
  • Instruments For Viewing The Inside Of Hollow Bodies (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
UY0001034550A 2011-12-21 2012-12-21 Bencilpirazoles sustituidos UY34550A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11194896 2011-12-21

Publications (1)

Publication Number Publication Date
UY34550A true UY34550A (es) 2013-07-31

Family

ID=47458948

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034550A UY34550A (es) 2011-12-21 2012-12-21 Bencilpirazoles sustituidos

Country Status (9)

Country Link
US (1) US9643953B2 (zh)
EP (1) EP2794596B1 (zh)
JP (1) JP6141866B2 (zh)
CN (1) CN104125957B (zh)
CA (1) CA2859779A1 (zh)
ES (1) ES2638144T3 (zh)
HK (1) HK1203196A1 (zh)
UY (1) UY34550A (zh)
WO (1) WO2013092512A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
CN104066731B (zh) * 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
KR102362835B1 (ko) 2013-03-15 2022-02-14 사이클리온 테라퓨틱스, 인크. ｓＧＣ 자극인자
CA2907730A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
EP2976335A1 (en) * 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
JP2016514718A (ja) * 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト ３−ヘテロアリール置換インダゾール類
CA2916103A1 (en) * 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
US20160168130A1 (en) * 2013-06-21 2016-06-16 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
US9745285B2 (en) 2013-06-21 2017-08-29 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
JP2016526540A (ja) * 2013-06-21 2016-09-05 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンジルピラゾール
CA2916116A1 (en) * 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CN105764893A (zh) * 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
CA2933250A1 (en) * 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2015193339A1 (en) 2014-06-17 2015-12-23 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107001331A (zh) 2014-09-19 2017-08-01 拜耳制药股份公司 作为bub1抑制剂的苄基取代的吲唑
JP6704398B2 (ja) 2015-01-28 2020-06-03 バイエル ファーマ アクチエンゲゼルシャフト ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
JP2018522847A (ja) 2015-06-17 2018-08-16 バイエル ファーマ アクチエンゲゼルシャフト ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類
WO2017102649A1 (en) * 2015-12-16 2017-06-22 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
ES2775782T3 (es) 2016-03-15 2020-07-28 Bayer Cropscience Ag Sulfonilamidas sustituidas para combatir parásitos animales
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
EP3601279B1 (de) 2017-03-31 2023-10-18 Bayer Animal Health GmbH Trizyklische carboxamide zur bekämpfung von arthropoden
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
IL301532A (en) 2020-09-23 2023-05-01 Scorpion Therapeutics Inc History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
BR112023006531A2 (pt) 2020-10-09 2023-10-03 Scorpion Therapeutics Inc Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) * 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US7569592B2 (en) 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
WO2010000001A1 (en) 2008-07-02 2010-01-07 Karen Gasparyan Bar clamping and tightening tool
CN102666537A (zh) 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 治疗黄病毒科病毒感染的氮杂吲唑
MA33926B1 (fr) * 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
US20130178475A1 (en) * 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
CA2872933A1 (en) 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment cancer
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
EP2976335A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
JP2016514718A (ja) 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト ３−ヘテロアリール置換インダゾール類
CA2907730A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
US20160168130A1 (en) 2013-06-21 2016-06-16 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
US9745285B2 (en) 2013-06-21 2017-08-29 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CA2916103A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
CA2916116A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
JP2016526540A (ja) 2013-06-21 2016-09-05 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンジルピラゾール

Also Published As

Publication number Publication date
US20140315934A1 (en) 2014-10-23
JP2015506336A (ja) 2015-03-02
JP6141866B2 (ja) 2017-06-07
CN104125957A (zh) 2014-10-29
ES2638144T3 (es) 2017-10-18
EP2794596A1 (en) 2014-10-29
US9643953B2 (en) 2017-05-09
WO2013092512A1 (en) 2013-06-27
HK1203196A1 (zh) 2015-10-23
CA2859779A1 (en) 2013-06-27
EP2794596B1 (en) 2017-05-31
CN104125957B (zh) 2016-05-25

Similar Documents

Publication Publication Date Title
UY34550A (es) Bencilpirazoles sustituidos
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY34523A (es) Derivados de betulina
UY34374A (es) Benzilindazoles sustituidos
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
UY34817A (es) Tienopirimidinas
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34034A (es) Triazolopiridinas
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY4175Q (es) Reloj pulsera
UY34591A (es) Compuestos de imidazopirrolidinona
UY34365A (es) Compuestos heterociclicos
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34039A (es) Compuestos fungicidas
UY34515A (es) Triazolopiridinas sustituidas
UY34006A (es) Imidazopiridazinas
UY33930A (es) Inhibidores novedosos de quinasas
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34138A (es) Antagonistas de trpv4

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020